AbbVie is acquiring Landos Biopharma, whose lead drug is a small molecule that takes a novel approach to treating ulcerative colitis. Preliminary proof-of-concept data from a Phase 2 study are expected later this year.
Landos Biopharma Inc. (LABP) shares are surging more than 169 percent on Monday morning trade after the company announced a definitive agreement to be acquired by AbbVie Inc.
The following bids, mergers,
acquisitions and disposals were reported by 2000 GMT on Monday: The Spanish government has acquired a 3% stake in
telecoms group Telefonica.
Landos Biopharma, Inc (NASDAQ:LABP) Short Interest Update theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Landos Biopharma, Inc (NASDAQ:LABP) Short Interest Update themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.